Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Truist Financial Corp

Truist Financial Corp increased its stake in Novo Nordisk A/S (NYSE:NVO) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 597,059 shares of the company’s stock after buying an additional 9,450 shares during the quarter. Truist Financial Corp’s holdings in Novo Nordisk A/S were worth $61,766,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. CNB Bank acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $26,000. Pacific Center for Financial Services grew its stake in Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares in the last quarter. Valued Wealth Advisors LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at approximately $28,000. Copeland Capital Management LLC grew its stake in Novo Nordisk A/S by 100.0% during the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after purchasing an additional 141 shares in the last quarter. Finally, Bell Investment Advisors Inc grew its stake in Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on NVO shares. BMO Capital Markets started coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective for the company. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective for the company. UBS Group started coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Trading Up 0.8 %

NYSE:NVO opened at $126.85 on Friday. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $126.86 and its two-hundred day moving average is $112.11. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The company has a market cap of $569.24 billion, a PE ratio of 46.89, a P/E/G ratio of 2.12 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The company had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. On average, analysts predict that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were issued a $0.664 dividend. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.